171 related articles for article (PubMed ID: 35196847)
1. Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore.
Chan WSA; Wong Y; Oon HHB; Theng CTS; Chong WS
Singapore Med J; 2023 Jul; 64(7):434-438. PubMed ID: 35196847
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
4. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Zhu X; Zheng M; Song M; Shen YK; Chan D; Szapary PO; Wang B;
J Drugs Dermatol; 2013 Feb; 12(2):166-74. PubMed ID: 23377389
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
Croxtall JD
Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
[TBL] [Abstract][Full Text] [Related]
11. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
12. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study.
Philipp S; Menter A; Nikkels AF; Barber K; Landells I; Eichenfield LF; Song M; Randazzo B; Li S; Hsu MC; Zhu Y; DePrimo S; Paller AS
Br J Dermatol; 2020 Oct; 183(4):664-672. PubMed ID: 32173852
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
Strober B; Menter A; Leonardi C; Gordon K; Lambert J; Puig L; Photowala H; Longcore M; Zhan T; Foley P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2830-2838. PubMed ID: 32320088
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL).
Tsai TF; Ho JC; Song M; Szapary P; Guzzo C; Shen YK; Li S; Kim KJ; Kim TY; Choi JH; Youn JI;
J Dermatol Sci; 2011 Sep; 63(3):154-63. PubMed ID: 21741220
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
[TBL] [Abstract][Full Text] [Related]
18. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
Landells I; Marano C; Hsu MC; Li S; Zhu Y; Eichenfield LF; Hoeger PH; Menter A; Paller AS; Taieb A; Philipp S; Szapary P; Randazzo B
J Am Acad Dermatol; 2015 Oct; 73(4):594-603. PubMed ID: 26259989
[TBL] [Abstract][Full Text] [Related]
20. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]